JUNS revenueQ2 2026$24.2K
- QoQ
- +30.0%
JUNS revenue was $24.2K in fiscal Q2 2026 (ended Jun 30, 2026), up 30.0% from the prior quarter. For the full fiscal 2025 it was $21.8K, compared with $0 in fiscal 2024.
Jupiter Neurosciences Inc. (JUNS) financials
For fiscal 2025 (ended Dec 31, 2025), Jupiter Neurosciences Inc. reported $21.8K of revenue and -$8.64M of net income.
- Revenue, FY2025
- $21.8K
- Net income, FY2025
- -$8.64M
- Net margin
- -39662.8%
- EPS, diluted, FY2025
- -$18.75
- Cash
- $1.52M
- P/S
- 132.78
- Market cap
- $2.9M
FY2024FY2025
FY2023FY2025
JUNS revenue and earnings growth
JUNS net incomeQ2 2026-$2.27M
JUNS net income was -$2.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.25M a year earlier. For the full fiscal 2025 it was -$8.64M, compared with -$2.44M in fiscal 2024.
JUNS EPSQ2 2026-$4.08
JUNS diluted EPS was -$4.08 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.09 a year earlier. For the full fiscal 2025 it was -$18.75, compared with -$6.00 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $21.8K | $0 | - |
| Cost of revenue | $4.2K | - | - |
| Gross profit | $17.6K | - | - |
| Research and development | $2.09M | $492.7K | $954.8K |
| Selling, general and admin | $6.84M | $2.60M | $2.92M |
| Operating income | -$8.91M | -$3.09M | -$3.87M |
| Interest expense | $66.0K | $248.4K | $218.7K |
| Net income | -$8.64M | -$2.44M | -$4.78M |
| EPS, basic | -$18.75 | -$6.00 | -$13.50 |
| EPS, diluted | -$18.75 | -$6.00 | -$13.50 |
| Diluted shares | 461,714.507 | 383,773.933 | 352,068.12 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $3.79M | $3.77M | $28.5K |
| Receivables | $2.6K | - | - |
| Inventory | $159.8K | - | - |
| Current assets | $4.82M | $4.65M | $28.7K |
| Total assets | $5.56M | $6.20M | $148.6K |
| Current liabilities | $7.40M | $2.01M | $5.77M |
| Long-term debt | - | - | $106.7K |
| Total debt | - | - | $106.7K |
| Total liabilities | $7.40M | $2.03M | $5.95M |
| Shareholders' equity | -$1.83M | $4.17M | -$5.80M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$5.41M | -$3.91M | -$481.0K |
| Financing cash flow | $5.43M | $7.65M | $445.0K |
| Stock-based compensation | $2.42M | $1.84M | $1.20M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.2K | $18.7K | - | - | - | $0 | - | - | - | - | - | - |
| Cost of revenue | $3.2K | $4.4K | - | - | - | - | - | - | - | - | - | - |
| Gross profit | $21.1K | $14.3K | - | - | - | - | - | - | - | - | - | - |
| Research and development | $600.4K | $411.0K | $43.7K | $816.7K | $759.4K | $466.7K | $201.0K | $91.9K | $101.1K | $98.7K | $244.7K | $239.5K |
| Selling, general and admin | $2.16M | $1.57M | $2.78M | $1.48M | $1.51M | $1.07M | $1.26M | $401.6K | $456.0K | $472.0K | $290.9K | $1.20M |
| Operating income | -$2.74M | -$1.96M | -$2.81M | -$2.30M | -$2.26M | -$1.54M | -$1.46M | -$493.5K | -$557.1K | -$570.7K | -$535.6K | -$1.44M |
| Interest expense | $90.6K | $118.6K | $62.5K | $1.2K | $1.1K | $1.2K | $30.5K | $107.4K | $56.3K | $65.8K | $58.4K | $80.6K |
| Net income | -$2.27M | -$2.06M | -$2.58M | -$2.29M | -$2.25M | -$1.53M | -$1.53M | -$591.0K | $313.1K | -$634.1K | -$429.6K | -$1.77M |
| EPS, basic | -$4.08 | -$4.50 | -$4.66 | -$5.25 | -$5.09 | -$3.75 | -$3.75 | -$1.50 | $0.75 | -$1.50 | - | -$5.25 |
| EPS, diluted | -$4.08 | -$4.50 | -$4.66 | -$5.25 | -$5.09 | -$3.75 | -$3.75 | -$1.50 | $0.75 | -$1.50 | - | -$5.25 |
| Diluted shares | 557,567 | 470,074.507 | - | 453,865.413 | 442,413 | 441,384.8 | - | 414,209.173 | 407,897.48 | 353,685.4 | - | 352,028.707 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.52M | $2.36M | $3.79M | $723.8K | $1.88M | $2.71M | $3.77M | $253 | - | - | $28.5K | - |
| Receivables | $10.2K | - | $2.6K | - | - | - | - | - | - | - | - | - |
| Inventory | $135.3K | $148.1K | $159.8K | - | - | - | - | - | - | - | - | - |
| Current assets | $2.55M | $3.41M | $4.82M | $1.63M | $2.82M | $3.61M | $4.65M | $514 | - | - | $28.7K | - |
| Total assets | $3.72M | $3.95M | $5.56M | $2.58M | $3.97M | $4.96M | $6.20M | $85.5K | - | - | $148.6K | - |
| Current liabilities | $3.88M | $6.73M | $7.40M | $2.52M | $2.63M | $1.89M | $2.01M | $5.68M | - | - | $5.77M | - |
| Long-term debt | - | - | - | - | - | - | - | $121.7K | - | - | $106.7K | - |
| Total debt | - | - | - | - | - | - | - | $121.7K | - | - | $106.7K | - |
| Total liabilities | $4.08M | $6.73M | $7.40M | $2.52M | $2.63M | $1.90M | $2.03M | $5.84M | - | - | $5.95M | - |
| Shareholders' equity | -$366.0K | -$2.78M | -$1.83M | $57.4K | $1.34M | $3.06M | $4.17M | -$5.75M | -$5.36M | -$6.02M | -$5.80M | -$6.27M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.29M | -$1.43M | -$2.37M | -$1.15M | -$828.2K | -$1.06M | -$3.70M | -$42.6K | -$107.5K | -$65.2K | -$161.1K | - |
| Financing cash flow | $1.45M | $5.5K | - | - | - | - | $7.47M | $28.0K | $114.0K | $45.0K | $130.0K | - |
| Stock-based compensation | $491.0K | $501.0K | $463.2K | $1.07M | $462.5K | $421.5K | $1.01M | $195.1K | $277.0K | $355.3K | $213.2K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 86.9% | 76.6% | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -11313.4% | -10524.3% | - | - | - | - | - | - | - | - | - | - |
| Net margin | -9380.9% | -11054.9% | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 0.66 | 0.51 | 0.65 | 0.65 | 1.07 | 1.91 | 2.31 | 0.00 | - | - | 0.00 | - |
Source: XBRL data Jupiter Neurosciences Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-75, first reported Aug 14, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
JUNS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| JUNS | $21.8K | - | -$8.64M | -39662.8% | $2.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
JUNS FAQ
7 questionsWhat is JUNS revenue?
Jupiter Neurosciences Inc. (JUNS) reported $21.8K of revenue for fiscal 2025 (ended Dec 31, 2025).Is JUNS profitable?
No. Jupiter Neurosciences Inc. reported a net loss of $8.64M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does JUNS have?
Jupiter Neurosciences Inc. reported $1.52M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is JUNS gross margin?
Jupiter Neurosciences Inc.'s gross profit was $17.6K on $21.8K of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 80.6%.What is JUNS earnings per share?
Diluted earnings per share were -$18.75 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did JUNS last report financial results?
The latest statements here come from Jupiter Neurosciences Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this JUNS financial data come from?
Quantisnow builds these statements from the structured XBRL data Jupiter Neurosciences Inc. files with the SEC. It is provided for information only and is not investment advice.